Skip to main content
Premium Trial:

Request an Annual Quote

NIH Plans $15M for Phase II COBRE Grants

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Center for Research Resources plans to award $15 million in 2011 for Phase III funding for its Centers of Biomedical Research Excellence (COBRE) program.

Funded through the Institutional Development Award Program, the COBRE grants support development of the biomedical research infrastructure and faculty that are necessary to establish and maintain core facilities and multidisciplinary, collaborative programs based on shared scientific interests.

Phase I of the COBRE grants funds development of research infrastructure and junior investigators, and Phase II strengthens the center through improvement of both faculty and facilities. Phase III of the program supports maintaining COBRE research cores that have already been funded, and sustaining a collaborative, multidisciplinary research environment by funding pilot projects and mentoring and training components.

NCRR expects that this funding will support up to 15 COBRE center projects with up to $750,000 per year in direct costs.

These COBRE Phase III: Transitional Centers grants will support administrative cores that provide mentoring and training, core resources, and facilities, including supplies, service contracts, and key management personnel, and it will support equipment upgrades and replacements.

In December, 2009, Tulane University was awarded $10.5 million in COBRE funding to extend a 2004 grant to fund a research core affiliated with the Tulane Cancer Center and the Louisiana Cancer Research Consortium. And in August of last year Rhode Island Hospital won an $11 million COBRE grant to support a Center for Cancer Research and Development.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more